Earlier researches in support of antifibrotic activity of AcSDKP includes the inhibition of TGF-β-induced expression of plasminogen activator inhibitor-1 and α2 collagen in human mesangial cells by inhibiting the smad 2/3 signaling pathway [17]; Shibuya et al. reported that AcSDKP prevented renal insufficiency and mesangial matrix expansion in diabetic db/db mice [18]; AcSDKP showed protective effects in various experimental animal models [19,20]. This evidence concerns the gene TMSB4X and Renal insufficiency.